Press Coverage

Safety Watchdog Questions FDA's Approval of Parkinson's Psychosis Drug

Article describes findings from an ISMP QuarterWatch report that reviewed documents from the FDA's evaluation of pimavanserin (Nuplazid), a drug approved to treat Parkinson's disease patients with psychosis, and found a number of questions about the drug's safety and efficacy have been left unanswered. The report calls for stronger warnings on the drug label and a re-evaluation of whether Nuplazid has benefits that outweigh its still poorly defined risks.

For the full text, visit CNN online.

More News

Since the 2021-2022 influenza (flu) vaccine became available in September, the Institute for Safe Medication Practices (ISMP) has received multiple reports of mix-ups. Some patients have consented to a flu vaccine but received one of the COVID-19 vaccines instead, while others have received the flue